Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis

Table 4 Stratified multivariable Cox model analyses

BM Lesions	WBRT (Gy)	OS			iPFS
BM Lesions	WBRT (Gy)	HR	95%CI	p^a	HR	95%CI	p^a
1–3 (N₁ = 338)	none	1.000		ref.	1.000		ref.
	< 30	1.607	(0.876–2.946)	0.125	1.660	(0.915–3.009)	0.095
	30–39	0.781	(0.432–1.413)	ns	0.700	(0.408–1.201)	0.196
	≥40	0.639	(0.403–1.012)	0.056	0.592	(0.380–0.924)	0.021
	≥40 vs. 30–39 (ref.)	0.818	(0.456–1.466)	0.499	0.846	(0.505–1.417)	0.526
≥4 (N₂ = 257)	none	1.000		ref.	1.000		ref.
	< 30	0.977	(0.487–1.957)	ns	1.880	(0.915–3.863)	0.086
	30–39	0.589	(0.348–0.996)	0.048	0.699	(0.421–1.159)	0.165
	≥40	0.514	(0.328–0.806)	0.004	0.624	(0.401–0.969)	0.036
	≥40 vs. 30–39 (ref.)	0.873	(0.540–1.413)	0.581	0.892	(0.558–1.426)	0.634

BM brain metastases; WBRT whole brain radiotherapy; OS overall survival; iPFS intracranial progression-free survival; HR hazard ratio; 95%CI 95% confidence interval; ns not significant with p >0.20; ref. reference
^a from the multivariable Cox model analysis without BM lesion group as one covariate

ISSN: 1471-2407